Allarity Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Allarity Therapeutics, Inc. (Nasdaq: ALLR) on September 9, 2022. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Cambridge, MA. The report primarily addresses a change in the Company's independent registered public accounting firm.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and auditor changes rather than financial performance data.
Material Changes
- Change in Certifying Accountant: On September 9, 2022, the Audit Committee approved the engagement of Wolf & Company, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2022, effective immediately.
- Consultation History: The Company confirmed that during the two most recent fiscal years (2020 and 2021) and the interim period through September 9, 2022, there were no consultations with Wolf & Company regarding accounting principles, audit opinions, disagreements, or reportable events.
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure referencing a press release issued on September 12, 2022, regarding the auditor engagement. The document does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclosure regarding the auditor change.
Investor Verification Checklist
- Verify the reasons for the departure of the previous independent registered public accounting firm, which are not detailed in this specific 8-K text.
- Review the attached press release (Exhibit 99.1) for additional context on the auditor transition.
- Monitor upcoming financial filings (10-K or 10-Q) for the first financial statements audited by Wolf & Company, P.C.
- Confirm the Company's status as an emerging growth company and any associated reporting exemptions.